Bob Brown joined Dicerna as Senior Vice President, Research in 2008, and in 2012 was appointed Chief Scientific Officer and Executive Vice President of R&D.
Prior to Dicerna, Dr. Brown spent 10 years at Genta Inc., where he was Head of Biological Research and later Vice President, Research and Technology. During his tenure with Genta, Dr. Brown became one of the first biopharmaceutical executives to contribute to all stages of the development of a systemically administered oligonucleotide therapeutic, from research bench to regulatory review, working with clinicians and study investigators on trial design, execution and interpretation of results. Dr. Brown was also the head of Salus Therapeutics, an RNAi startup that was acquired by Genta and operated as a separate business unit. While at Genta, Dr. Brown generated more than 75 patents and patent applications covering the chemistry, structure and function, formulation, in vivo delivery, and use of nucleic acid therapeutics, including RNAi and antisense, as well as formulation and application of other novel therapeutics.
In addition to his roles with Genta, Dr. Brown co-founded and co-invented the founding technology for Oasis Biosciences where he served as Vice President, Research until its acquisition by GenProbe.
Dr. Brown holds Bachelor of Science degrees in chemistry and biology from the University of Washington and a Ph.D. in molecular biology from the University of California, Berkeley.